If your work involves life sciences dealmaking, you know it’s the time of year to start firming up your plans for the week of the J.P. Morgan Healthcare Conference. In the last 10 years, the second week of January in San Francisco has evolved from a J.P. Morgan private meeting for healthcare investors to a week
There are a lot of opportunities to be had creating mobile health apps for consumers. But there are still plenty of questions to be answered about how to build sustainable businesses. Who will pay for mhealth products? How will they be priced? At the recent Digital Health Investor Summit, co-hosted by Fenwick & West and Rock Health, the speakers addressed several key issues around revenue generation in this emerging sector.
Anne DeGheest of Healthtech Capital pointed out “apps are easy to launch, but have a high attrition rate.” Seasoned technology investor Sundeep Peechu of Felicis echoed Anne’s concerns and conveyed several mobile product axiom:
- Apps have won
- Winning apps are “mobile first”
- Consumers are willing to pay, but not enough
Fenwick & West has been a long-time supporter of QB3, as well as the biotech community at UCSF. Therefore, we are delighted that QB3 (California Institute for Quantitative Biosciences ), the San Francisco Office of Economic Workforce Development, and the San Francisco Center for Economic Development (SFCED) have launched a joint public-private partnership to support startup creation and attract industry and investors to the thriving innovation zone in San Francisco’s Mission Bay. Also, congratulations to Sally Ann Reiss, who has been appointed director of BioSF.